Mr. Elam has been founding, managing and advising healthcare and technology companies for more than 30 years. 

Prior to founding Rezolute, Mr. Elam held various senior leadership positions in the industry including Senior Vice President at Nektar Therapeutics (NASDAQ: NKTR) where he ran the Pulmonary Business Unit and was instrumental in streamlining the organization and reshaping its pipeline. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Aerogen in Ireland and Pearl Therapeutics, which was acquired by AstraZeneca for $1 billion. Mr. Elam also played a fundamental role in launching Savara, Inc. (NASDAQ: SVRA) where he helped shape the company’s direction and path forward with his rare disease and pulmonary expertise. Mr. Elam also was the Co-Founder and Chief Financial Officer of e2open (NYSE: ETWO), a web-based supply chain platform company serving various industries including healthcare. Early in his career, Mr. Elam was a corporate partner at the law firm of Wilson Sonsini Goodrich & Rosati, where he advised both emerging growth companies and mature corporations such as Genentech and Hewlett Packard, and negotiated several notable deals, including the sale of Steve Jobs’ company, Next, to Apple. 

Throughout his career, Mr. Elam has served on the board of directors of various healthcare companies in the US, Europe and Asia. He currently serves on the board of Rezolute and Savara. 

Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.